ResQ Pharma, Inc., a Chicago, IL-based biopharmaceutical company, completed a $725k second seed equity funding.
To date, the company has raised $1.05m.
ResQ Pharma, which focuses on commercializing LipidRescue™ Therapy (LRT), a treatment for various drug overdoses and poisonings*, is scheduled to meet the U.S. Food & Drug Administration (FDA) on September 29th 2016 regarding an application for LRT as a treatment for local anesthetic systemic toxicity (LAST). The company also filed for Orphan Drug Designation applications in both the US and European Union.
* LRT refers to the administration of a lipid emulsion with the intent of reducing the life-threatening clinical manifestations of toxicity from excessive doses of certain lipophilic drugs.